The study began with a methodological choice that sets it apart from much of the antibiotic adjuvant literature. Rather than screening libraries of chemicals and then struggling to work out how the hits function, the researchers used CRISPR interference, or CRISPRi, to build a genome-wide gene repression library in Escherichia coli and asked which genes, when silenced, make bacteria more vulnerable to the fluoroquinolone ciprofloxacin. Because CRISPRi represses genes reversibly and without killing the cell, the team could distinguish genes whose loss specifically sensitizes bacteria to antibiotic stress from genes that are simply essential for growth. They exposed the library to ciprofloxacin concentrations ranging from one-eighth to sixteen times the minimum inhibitory concentration, then used high-throughput amplicon sequencing of surviving clones to quantify which guide RNAs had been depleted.

The results pointed unambiguously toward DNA maintenance. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed strong enrichment of sensitivity-related genes in homologous recombination, mismatch repair, and nucleotide excision repair, while Gene Ontology analysis highlighted DNA repair and recombination, the SOS response, membrane organization, and efflux pump regulation. Within the homologous recombination pathway, repression of dnaE, dnaQ, holD, polA, recA, recB, recC, ruvA, and ruvB left bacterial growth essentially untouched in the absence of antibiotics but sharply reduced survival as ciprofloxacin concentrations rose, a pattern the authors describe as synthetic lethality between DNA repair deficiency and antibiotic-induced genotoxic stress. Among these, recA, polA, dnaE, and holD showed the most consistent potentiating effect, not only against quinolones but also against beta-lactams, aminoglycosides, and nitrofurantoin.

Homologous recombination is an attractive target precisely because it is so conserved. Core components such as RecA and RuvABC maintain genome stability, repair DNA damage, and mediate horizontal gene transfer in virtually all bacteria, and their catalytic domains and DNA-binding motifs are nearly identical in organisms as different as E. coli and Bacillus subtilis. To validate the screen, the team deleted several nonessential genes, including recA, polA, holD, ruvB, and dnaQ. Although minimum inhibitory concentrations were unchanged, all five deletion strains showed significantly reduced survival after exposure to one or more bactericidal antibiotics, and recA deletion reduced survival under every bactericidal drug tested while leaving susceptibility to bacteriostatic agents such as tetracycline and tigecycline intact.

The mechanistic story that emerged was broader than simple loss of DNA repair. Compared with the wild-type parent strain, the recA-deficient bacteria displayed significant membrane damage, with increased permeability and fluidity and a reduced membrane potential, all of which promote antibiotic influx. Ethidium bromide accumulation assays revealed impaired efflux pump function, and enzyme-linked immunosorbent measurements confirmed heightened intracellular accumulation of ciprofloxacin. The mutants also produced elevated levels of reactive oxygen species, showed attenuated antioxidant capacity, and suffered pronounced declines in ATP production, respiratory rate, and the transmembrane proton gradient, with swimming motility compromised as well. The authors argue that these phenotypes stem not only from the loss of RecA’s recombinase activity but also from secondary disruption of the SOS response and broader transcriptional dysregulation, effectively turning RecA into a global regulator of bacterial stress physiology.

Perhaps the most striking discovery was that RecA also facilitates the horizontal spread of resistance. Because ATP production, respiration, and motility all regulate plasmid conjugation, the team tested whether recA deficiency affects plasmid transfer. Transconjugation experiments with the RP4-7 plasmid showed that recA-deficient strains, whether serving as donors or recipients, transferred the plasmid at significantly reduced frequency, with the defect most severe when both partners lacked RecA. A target that simultaneously sensitizes bacteria to antibiotics and blocks the dissemination of resistance genes is, in principle, a doubly valuable asset for anti-resistance strategies.

With the target validated genetically, the researchers tested three ways of inhibiting it. First, they delivered a CRISPRi system targeting recA by bacterial conjugation; transcriptional knockdown was successful and sensitized cells to ciprofloxacin and meropenem, but the effect was modest, reflecting the practical limits of plasmid-based delivery. Second, they exploited RecX, a natural RecA inhibitor that suppresses RecA-mediated strand exchange even at substoichiometric levels. Overexpression of recX reduced survival under quinolone treatment in a dose-dependent manner, and a synthetic twenty-amino-acid alpha-helical peptide derived from the RecX-RecA structure, fused to a cell-penetrating motif, potentiated quinolone killing, though its activity did not extend to beta-lactams, aminoglycosides, or colistin.

The third strategy proved the most powerful. Computational docking of a library of 135 candidate compounds against RecA identified cisplatin, the well-known platinum-based anticancer drug, as the strongest potentiator. Cisplatin significantly enhanced ciprofloxacin’s bactericidal effect against wild-type E. coli but showed no synergy in the recA deletion strain, demonstrating that the interaction is RecA-dependent. Surface plasmon resonance confirmed direct, concentration-dependent binding of cisplatin to RecA between 25 and 400 micromolar, with a dissociation constant of 40.3 micromolar, and comet assays revealed DNA fragmentation in cisplatin-treated cells resembling that of recA-deficient mutants. Time-kill assays showed a three-log reduction in viability within twenty-four hours at 8 micrograms per milliliter of cisplatin, with survival falling below the detection limit at 16 micrograms per milliliter after forty-eight hours. The synergy held against twenty multidrug-resistant clinical E. coli isolates and extended to quinolones, beta-lactams, aminoglycosides, polymyxins, and rifampicin in E. coli, Klebsiella pneumoniae, Proteus mirabilis, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecalis. Other platinum drugs, including lobaplatin, nedaplatin, carboplatin, and oxaliplatin, also potentiated antibiotics, though more weakly. Critically, serial passaging showed that cisplatin substantially delayed the emergence of ciprofloxacin resistance.

Cisplatin also suppressed conjugative transfer of clinically critical resistance plasmids, including those carrying tet(X4), bla NDM-5, and mcr-1, across a wide range of temperatures, pH values, plasmid incompatibility types, and donor-recipient combinations spanning E. coli, Salmonella Typhimurium, and K. pneumoniae. In animal models, the combination therapy achieved a seventy-five percent survival rate in Galleria mellonella larvae infected with a multidrug-resistant isolate, significantly outperforming either monotherapy, and reduced bacterial loads in the colon, liver, spleen, lung, and kidney in mouse intestinal and peritonitis-sepsis models while lowering pro-inflammatory cytokines and raising anti-inflammatory ones. In vivo transconjugation assays showed that cisplatin curtailed plasmid transfer in the mouse intestine within forty-eight hours without disturbing bacterial colonization. Safety testing was encouraging: hemolysis remained below five percent at 160 micrograms per milliliter, twenty times the synergistic dose, HEK293T cell viability exceeded ninety-five percent at the same concentration, and histopathology of five major organs in treated mice appeared normal, though the authors caution that cisplatin’s known toxicity and off-target effects will require structural optimization and drug-drug interaction studies before clinical translation.

The work frames what the authors call a defense-targeting adjuvant concept: rather than attacking essential bacterial structures directly, adjuvants disable the resilience machinery that pathogens rely on to survive antibiotic stress. By identifying homologous recombination, and RecA in particular, as a conserved, broadly applicable vulnerability, the study offers a target-driven blueprint for discovering next-generation potentiators and a feasible path toward restoring the efficacy of the antibiotic arsenal already in hand.

Subject of Research: Targeting the bacterial homologous recombination pathway and RecA protein to develop broad-spectrum antibiotic adjuvants against multidrug-resistant pathogens

Article Title: A genome-wide CRISPRi screen identifies homologous recombination pathway as potential target for broad-spectrum antibiotic adjuvants

Article References: Zhang, H., Chen, B., Gu, L., Wang, C., Xu, L., Ji, X., Wang, J., Wang, Z., Xiao, X., & Liu, Y. (2026). A genome-wide CRISPRi screen identifies homologous recombination pathway as potential target for broad-spectrum antibiotic adjuvants. Journal of Advanced Research, 87, 947-962. https://doi.org/10.1016/j.jare.2025.12.015

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.015

Keywords: antibiotic resistance, antibiotic adjuvants, CRISPRi screen, homologous recombination, RecA, cisplatin, horizontal gene transfer, multidrug-resistant bacteria, DNA repair, SOS response, conjugation, antimicrobial potentiators

At the heart of the investigation lies the strategic use of human cell lines—hTERT RPE-1 TP53 knockout cells, HeLa S3 dCas9–ZIM3, and K562 dCas9–KRAB cells—cultured under precisely controlled hypoxic (3% oxygen) conditions. This fine-tuned environment mimics physiological conditions more accurately than traditional normoxia, offering a robust platform for dissecting the nuanced interplay of DDR pathways. The employment of CRISPRi, as opposed to knockout-based methods, circumvents confounding lethal effects of complete gene ablation while enabling graded repression, thereby capturing subtler genetic effects.

To craft their expansive dual-guide RNA library targeting 548 genes implicated in DNA repair, the team integrated computational predictions with empirical data from over 50 prior CRISPRi screens. This hybrid strategy prioritized sgRNAs based on growth phenotypes in multiple cancer cell types, including neuroblastoma lines, to ensure robust targeting of genes with essential and context-dependent roles. Notably, the library design incorporated mismatched sgRNA variants with calibrated partial activity, augmenting the sensitivity and specificity of interaction discovery.

The experimental workflow represents a tour de force in genetic screening technology. Cells were transduced at low multiplicity of infection with the dual-guide lentiviral library, maintaining high coverage to secure statistical power. After stringent antibiotic selection, cells underwent approximately ten population doublings, allowing genetic perturbation effects to manifest. Through deep sequencing of integrated sgRNA cassettes and meticulous bioinformatics pipelines including GEMINI analysis, the researchers quantified the log-fold changes in sgRNA abundance, extracting genetic interaction scores indicative of synthetic lethality or buffering relationships.

Emergent from this massive dataset is a high-resolution genetic interaction network outlining functional clusters of DNA repair genes. Intriguingly, clusters of genes encoding proteins involved in replication fork stability, homologous recombination, and translesion synthesis yielded strong synthetic lethal pairs, underscoring cooperative pathways essential for maintaining genomic integrity. Cross-referencing with STRING protein interaction databases revealed these clusters corresponded to physically interacting molecular machinery, validating the biological significance of the interactions detected.

Complementary assays employing dual-color flow cytometry enabled dynamic monitoring of competitive growth between cells harboring different sgRNA combinations, substantiating the synthetic lethal relationships predicted by the screen. Clonogenic survival and competitive growth experiments further confirmed the synergistic sensitivities to selective gene knockdowns, particularly when combined with DNA damaging agents. Such functional validations highlight the therapeutic promise of combining targeted gene repression with conventional chemotherapy or emerging DDR inhibitors.

At the molecular level, the study delved into the roles of FANCM and SMARCAL1—key DNA motor proteins involved in replication stress responses. These genes were subject to CRISPR-mediated knockout and further characterized using biochemical assays with purified proteins. In vitro unfolding assays demonstrated their ability to resolve complex DNA secondary structures, including cruciform DNA intermediates enriched at TA-rich repeats, suggesting a direct mechanistic role in protecting stalled replication forks from collapse.

ChIP–seq analysis illuminated genome-wide binding profiles of FANCM, SMARCAL1, and MRE11, revealing their preferential localization to genomic loci enriched in AT repeats and potential cruciform structures. These data further support a model where coordinated action of these proteins safeguards replication fork progression through challenging genomic landscapes. The synergistic relationship between FANCM and SMARCAL1, particularly under replication stress, was reinforced by epistasis analysis of double gene knockouts, which exhibited exacerbated DNA damage phenotypes.

Through incorporation of next-generation proteomics, the authors captured dynamic ubiquitin remnant modifications (diGly proteomics) across various perturbations. This approach spotlighted post-translational regulation pathways activated upon DNA damage, extending insights into the molecular crosstalk underpinning synthetic lethality. Phosphorylation and ubiquitination signatures unveiled potential regulatory nodes within the DNA repair network, offering targets for pharmacologic intervention.

Meticulous live-cell imaging using FUCCI reporters and H2B–GFP fusion proteins detailed cell cycle progression and mitotic abnormalities following gene knockdowns and small molecule treatments. Prolonged mitotic arrest and catastrophic chromosomal fragmentation were observed in synthetic lethal contexts, linking genetic perturbations to cell fate decisions and genome instability phenotypes. This dynamic visualization complements static molecular assays, providing a temporal dimension to the DDR landscape.

This comprehensive interrogation not only identifies novel lethal gene pairs with high translational relevance but also exemplifies the power of integrating sophisticated genetic tools with multi-omic profiling and live-cell analyses. The study lays a foundation for rational development of combinatorial therapies exploiting synthetic lethality in cancer, potentially overcoming resistance mechanisms and enhancing precision medicine strategies.

In conclusion, this expansive investigation charts an unprecedented map of synthetic lethal interactions within the DNA damage response, bridging molecular mechanisms with functional dependencies. Its integrative experimental design and extensive validation provide a roadmap for future efforts aiming to translate genetic vulnerabilities into therapeutic opportunities. As DNA repair remains a cornerstone of genome stability and cancer biology, such systematic exploration promises profound impacts on understanding and combating malignancies.

Subject of Research:
Synthetic lethality and genetic interactions in the DNA damage response.

Article Title:
Comprehensive interrogation of synthetic lethality in the DNA damage response.

Article References:
Fielden, J., Siegner, S.M., Gallagher, D.N. et al. Comprehensive interrogation of synthetic lethality in the DNA damage response. Nature (2025). https://doi.org/10.1038/s41586-025-08815-4

Image Credits:
AI Generated